Physician profile
Madhupreet Kaur
NPI 1043701832
$1,340.25
in general payments reported to CMS, 2019-2025
21 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $213 · 2024: $488 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,340.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $190.23 | 2023-2025 | |
| Lilly USA, LLC | $161.49 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $148.72 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.95 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $119.90 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.73 | 2023-2024 | Jardiance, Tradjenta, Ofev |
| Exact Sciences Corporation | $83.65 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $82.18 | 2024-2025 | Repatha, Otezla, Otezla |
| Seqirus USA INC | $51.07 | 2024-2025 | Flucelvax, Fluad |
| Glaxosmithkline, LLC. | $34.68 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $32.24 | 2024-2025 | Veozah |
| Tanabe Pharma America, INC. | $29.76 | 2025 | Radicava |
| Idorsia Pharmaceuticals US INC | $23.65 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $21.67 | 2025 | Auvelity |
| Lundbeck LLC | $18.41 | 2023 | Brintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.14 | 2023 | Nuedexta |
| Inari Medical, INC. | $16.43 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $15.91 | 2023 | Xarelto |
| Abbvie INC. | $13.93 | 2024 | |
| Esperion Therapeutics, INC. | $13.77 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $13.74 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhupreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.